InMed Pharmaceuticals Inc. (MTRI) stock
MTRINasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as INM
$15.61+3.41 (+27.94%)
Close on Nov 11, 2026Market cap $85.75MP/E –Yield –
InMed Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
InMed Pharmaceuticals's ebitda for the twelve months ending Sep 30, 2023 was -$6.77M. For fiscal 2023 it was -$7.75M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Jun 30, 2023 | -$7.75M | – |
| FY2022 | Jun 30, 2022 | -$18.41M | – |
| FY2021 | Jun 30, 2021 | -$10.08M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | -$2.48M | – |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | -$284.93K | – |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | -$1.95M | – |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | -$2.05M | – |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | -$3.46M | – |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | -$7.82M | – |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | -$3.42M | – |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | -$4.23M | – |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | -$2.94M | – |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | -$3.23M | – |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | -$3.07M | – |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | -$2.21M | – |
See a number that looks wrong?